PartnershipAug 5, 2026, 04:28 PM
RxSight Partners with Alcon, Receives $60M Upfront Payment
AI Summary
RxSight, Inc. announced a significant License, Collaboration and Development Agreement with Alcon Pharmaceuticals, Ltd., receiving a $60 million upfront payment for developing light-adjustable versions of Alcon's intraocular lenses. For the second quarter of 2026, the company reported total revenue of $33.7 million, including $6.5 million from the Alcon deal, and a net loss of $12.1 million. RxSight continues to experience net operating losses but believes existing cash resources are sufficient for at least the next 12 months.
Key Highlights
- Entered License, Collaboration and Development Agreement with Alcon Pharmaceuticals.
- Received a $60 million upfront cash payment from Alcon.
- Reported Q2 2026 total revenue of $33.7 million, including $6.5 million from collaboration.
- Incurred a net loss of $12.1 million for the second quarter of 2026.
- Cash, cash equivalents, and short-term investments totaled $208.8 million as of June 30, 2026.
- Expects to continue incurring net operating losses into the foreseeable future.
- Believes existing cash resources are sufficient for at least the next 12 months.
Price Impact
More from RXST